The CenterWatch Weekly, December 19, 2016

Monday, December 19, 2016

Center Point’s siteless technology disrupts CRO sector, offers more humanistic, safer approach

In a series of announcements this week, Center Point Clinical Services unveiled what it calls the first siteless technology model for pharmaceutical trial research in the CRO industry. The announcement appears to come as a surprise within the CRO industry, perhaps even a shock. Only one of several CROs contacted for comment responded to CenterWatch inquires.

CRISPR/Cas9 market expanding, but questions remain

Recent announcements reflect the enormous excitement and activity surrounding CRISPR/Cas9. Biotech company Intellia Therapeutics announced the opening of its new head­quarters in Cambridge, Massachusetts, in early December. The company is pioneering therapeutic applications of CRISPR/Cas9, a revolutionary genome editing technology that researchers hope will eventually gener­ate treatments for a broad range of diseases.

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!